Announcements

June 7, 2024

Genetic Signatures (ASX:GSS) – Completion of Institutional Entitlement Offer and Placement

June 4, 2024

Genetic Signatures (ASX:GSS) – Proposed issue of securities

June 4, 2024

Genetic Signatures (ASX:GSS) – Proposed issue of securities

June 4, 2024

Genetic Signatures (ASX:GSS) – Announces $30 million Capital Raising

June 4, 2024

Genetic Signatures (ASX:GSS) – Allison Rossiter appointed as CEO

Genetic Signatures welcomes Allison Rossiter, as the incoming CEO.

View announcement

May 31, 2024

Genetic Signatures (ASX:GSS) – Trading Halt 31st May 2024

Commencement of normal trading on Thursday, 6 June 2024.

View announcement

May 27, 2024

Genetic Signatures (ASX:GSS) – Decision to Cease Development of US Respiratory Product

May 18, 2024

Genetic Signatures (ASX:GSS) – Ceasing to be a substantial holder

May 3, 2024

Genetic Signatures (ASX:GSS) – Application for quotation of securities

April 30, 2024

Genetic Signatures (ASX:GSS) – Final Director’s Interest Notice